Statement: one solitary case of diarrhea has arisen in the secondary clinical trial, on the other hand, an excess of 14 different aes have been observed in the cohorts of the primary clinical trial.
Primary_evidence: Adverse Events 1:   Total: 59/373 (15.82%)   Neutropenia 14/373 (3.75%)   Febrile neutropenia 10/373 (2.68%)   Leukopenia 1/373 (0.27%)   Anaemia 2/373 (0.54%)   Lymphadenopathy 0/373 (0.00%)   cardiac failure 2/373 (0.54%)   Atrial fibrillation 1/373 (0.27%)   Pericardial effusion 2/373 (0.54%)   Cardiac failure congestive 1/373 (0.27%)   Cardiomyopathy 0/373 (0.00%) Adverse Events 2:   Total: 69/377 (18.30%)   Neutropenia 17/377 (4.51%)   Febrile neutropenia 10/377 (2.65%)   Leukopenia 4/377 (1.06%)   Anaemia 2/377 (0.53%)   Lymphadenopathy 1/377 (0.27%)   cardiac failure 1/377 (0.27%)   Atrial fibrillation 1/377 (0.27%)   Pericardial effusion 0/377 (0.00%)   Cardiac failure congestive 0/377 (0.00%)   Cardiomyopathy 1/377 (0.27%)
Secondary_evidence: Adverse Events 1:   Total: 0/92 (0.00%)   Diarrhea 0/92 (0.00%) Adverse Events 2:   Total: 1/93 (1.08%)   Diarrhea 1/93 (1.08%)